Free shipping on all orders over $ 500

Camrelizumab

Cat. No. M24808

All AbMole products are for research use only, cannot be used for human consumption.

Camrelizumab Structure
Synonym:

SHR-1210; INCSHR1210

Size Price Availability Quantity
100ug USD 150 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.

Chemical Information
CAS Number 1798286-48-2
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Shengxiang Ren, et al. J Thorac Oncol. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

[2] Yunpeng Yang, et al. Lancet Oncol. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

[3] Anthony Markham, et al. Drugs. Camrelizumab: First Global Approval

Related PD-1/PD-L1 Products
Avelumab (MSB0010718C)

Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1

Panaxadiol

Panaxadiol exists in ginseng root and has neuroprotective and anti-tumor functions. Panaxadiol inhibits the expression of programmed cell death ligand-1 (PD-L1) and tumor proliferation.

Fraxinellone

Fraxinellone was isolated from the root bark of the brassica family Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor that inhibits HIF-1α synthesis without affecting HIF-1α degradation. Fraxinellone has potential for cancer immunity by targeting PD-L1.

BMS202

Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity.

Sulfamethoxypyridazine

Sulfamethoxypyridazine is a long-acting sulfonamide for treatment of Dermatitis herpetiformis.

  Catalog
Abmole Inhibitor Catalog




Keywords: Camrelizumab, SHR-1210; INCSHR1210 supplier, PD-1/PD-L1, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.